Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
First for Women on MSN9h
Amycretin Shows Promising 22% Weight Loss in Trials-It May Rival OzempicDrug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...
As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...
Seeking Alpha on MSN11h
Metsera sees stock rally 54% following $275M IPOShares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.
Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...
More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...
While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...
The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback